Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
52 Acute Lymphocytic Leukemia Trials
Power is an online platform that helps thousands of Acute Lymphocytic Leukemia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
CAR T-cell Therapy for Lymphoma and Leukemia
Columbus, OhioThis trial tests the safety and best dose of a new treatment using modified immune cells (CAR T-cells) for patients with certain recurring or hard-to-treat lymphoid cancers. The treatment involves giving patients a brief period of chemotherapy followed by an infusion of these specially designed cells to target and kill cancer cells. Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas where durable remissions can be induced in patients with previously incurable chemotherapy-refractory disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:2+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active CNS Involvement, Active Malignancy, Uncontrolled Illness, Pregnancy, Others
Must Not Be Taking:Immunosuppressants, Live Vaccines
54 Participants Needed
LP-118 for Leukemia
Columbus, OhioThis trial tests a new oral drug, LP-118, taken regularly in adults with blood cancers that have returned or resisted other treatments. It aims to find the safest and most effective dose and see if it helps control the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:13+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent HSCT, Active Malignancies, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers, TdP Drugs
100 Participants Needed
Acalabrutinib + Pembrolizumab for Blood Cancers
Columbus, OhioThis study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
161 Participants Needed
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are:
* Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant?
* Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior Allogeneic Transplant, Uncontrolled Infection, Others
190 Participants Needed
Vaccine Therapy for Blood Cancers
Columbus, OhioThis randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
61 Participants Needed
Geriatric Care Optimization for Blood Cancers
Columbus, OhioThis clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
30 Participants Needed
CAR T-Cell Therapy for Leukemia and Lymphoma
Columbus, OhioThis pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
Patients will undergo screening, leukapheresis (cell collection), lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by the anti-CD19 CAR T cell infusion. The lymphodepleting chemotherapy is administered over four days IV to prepare the body for the CAR T cells. The anti-CD19 CAR-T cells are infused between 2-14 days after the last dose of chemotherapy. This study is designed for participants to begin lymphodepleting chemotherapy during the CAR T cell manufacture and receive a fresh cell infusion on the day that manufacturing is complete. Some patients may need more time in between the cell collection and the CAR T cell infusion, therefore, the cells may be manufactured and frozen prior to administration. Patients will be followed for a year after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:< 30
Sex:All
12 Participants Needed
BMF-219 for Blood Cancers
Cincinnati, OhioThis trial is testing a new oral drug called BMF-219 that blocks a protein involved in cancer growth. It is aimed at adults with specific types of blood cancers that have certain genetic changes. The goal is to see if this drug can stop the cancer cells from growing.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
55 Participants Needed
Palbociclib + Chemotherapy for Childhood Leukemia and Lymphoma
Cincinnati, OhioAINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are most commonly treated with ALL regimens. The proposed palbociclib starting dose for this study will be 50 mg/m\^2/day for 21 days.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:12 - 31
Sex:All
12 Participants Needed
Venetoclax Extension Study for Leukemia
Canton, OhioThe purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:All
Sex:All
165 Participants Needed
AVM0703 for Lymphoma
Canton, OhioThis is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 95
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Diabetes, Infections, Others
Must Not Be Taking:Antidepressants
144 Participants Needed
Calaspargase Pegol for Acute Lymphoblastic Leukemia
Cleveland, OhioThis trial is testing Calaspargase pegol, a medication for treating a specific type of blood cancer called Philadelphia-negative Acute Lymphoblastic Leukemia. The study aims to find the best dose and check the safety of the drug. Calaspargase pegol works by starving the cancer cells of a nutrient they need to survive.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:22 - 55
Sex:All
122 Participants Needed
CAR NK Cells for B-Cell Cancers
Cleveland, OhioThis is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
150 Participants Needed
CG-806 for Acute Myeloid Leukemia and High-Risk MDS
Cleveland, OhioThis study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
80 Participants Needed
CAR-T Cell Therapy for Lymphoma
Cleveland, OhioThe purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
36 Participants Needed
NK Cells + IL-2 + Vactosertib for Cancer
Cleveland, OhioThis trial tests a treatment for colorectal and certain blood cancers using special immune cells from healthy donors and two supportive drugs. It aims to boost the patient's immune system to better fight the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Involvement, HIV, Hepatitis, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
12 Participants Needed
Bone Marrow Transplant for Leukemia
Detroit, MichiganThis trial is testing the safety of using bone marrow from a deceased donor to treat patients with severe leukemia. The goal is to see if this new bone marrow can help produce healthy blood cells. Patients will be monitored closely for any side effects and overall effectiveness over several months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Living Donor, Prior HCT, Pregnancy, Infections, Others
Must Not Be Taking:Investigational Drugs
12 Participants Needed
CAR T-Cell Therapy for Lymphoma and Leukemia
Pittsburgh, PennsylvaniaThis trial uses CAR T-cell therapy, which involves modifying a patient's immune cells to fight cancer. It targets patients with B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia who may not respond to standard treatments. The treatment works by collecting, modifying, and reinfusing the patient's own immune cells to attack cancer cells. CAR T-cell therapy has shown remarkable success in treating B-cell malignancies, including B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:Anticancer, Corticosteroids, Immunosuppressants, Others
30 Participants Needed
FLT PET Imaging for Cancer
Detroit, MichiganRATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Nursing, Others
80 Participants Needed
FT819 for Blood Cancer
Louisville, KentuckyThis trial is testing a new drug called FT819, alone or with IL-2, in patients with certain blood cancers that have not responded to other treatments. FT819 targets cancer cells, and IL-2 boosts the immune system.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
54 Participants Needed
CAR T-Cell Therapy + Ibrutinib for Chronic Lymphocytic Leukemia
Chicago, IllinoisThis is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 100
Sex:All
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, Active CNS Lymphoma, Others
Must Be Taking:Ibrutinib
225 Participants Needed
Voruciclib + Venetoclax for Leukemia and Lymphoma
Charlottesville, VirginiaThis is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pneumonitis, CNS Involvement, Cardiovascular, Others
Must Not Be Taking:Warfarin, Anticancer, Investigational, Others
100 Participants Needed
PRT2527 + Zanubrutinib for Blood Cancers
Charlottesville, VirginiaThis trial is testing a new drug called PRT2527, which blocks a protein that helps cancer cells grow, in patients with certain blood cancers that have come back or did not respond to other treatments. It also tests PRT2527 in combination with another drug, zanubrutinib, which blocks a different protein involved in cancer growth. The goal is to find a safe and effective dose for these drugs.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
86 Participants Needed
IMGN632 for BPDCN
Buffalo, New YorkThis is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
179 Participants Needed
Turalio for Leukemia
Bethesda, MarylandBackground:
- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
Objectives:
- To find the highest safe dose and side effects of TURALIO(R). To see if it helps treat certain types of cancer.
Eligibility:
- People ages 3-35 with a solid tumor or leukemia that has returned or not responded to cancer therapies.
Design:
* Participants will be screened with:
* Medical history
* Physical exam
* Blood and urine tests
* Heart tests
* Scans or other tests of the tumor
* Participants will take TURALIO(R) as a capsule once daily for a 28-day cycle. They can do this for up to 2 years.
* During the study, participants will have many tests and procedures. They include repeats of the screening tests. Participants will keep a diary of symptoms.
* Participants with solid tumors will have scans or x-rays.
* Participants with leukemia will have blood tests. They may have a bone marrow sample taken.
* Some participants may have a biopsy.
* When finished taking TURALIO(R), participants will have follow-up visits. They will repeat the screening tests and note side effects.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:3 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, Hepatitis, Others
Must Not Be Taking:Warfarin, CYP3A4 Drugs
54 Participants Needed
CAR T-Cell Therapy for Leukemia and Lymphoma
Bethesda, MarylandBackground:
B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the laboratory with the CD19/CD22-CAR receptor gene through a process called 'lentiviral transduction (also considered gene therapy) and growing them to large numbers to use as a treatment for hematologic cancers in children and young adults.. Researchers want to see if giving modified CD19/CD22-CAR T cells to people with these cancers can attack cancer cells. In addition, the safety of giving these gene modified cells to humans will be tested at different cell doses. Additional objectives are to determine if this therapy can cause regression of B cell cancers and to measure if the gene modified cells survive in patients blood.
Objective:
To study the safety and effects of giving CD19/CD22-CAR T cells to children and young adults with B-cell cancer.
Eligibility:
People ages 3-39 with certain cancers that have not been cured by standard therapy. Their cancer tissue must express the CD19 protein.
Design:
A sample of participants blood or bone marrow will be sent to NIH and tested for leukemia.
Participants will be screened with:
Medical history
Physical exam
Urine and blood tests (including for HIV)
Heart and eye tests
Neurologic assessment and symptom checklist.
Scans, bone marrow biopsy, and/or spinal tap
Some participants will have lung tests.
Participants will repeat these tests throughout the study and follow-up.
Participants will have leukapheresis. Blood will be drawn from a plastic tube (IV) or needle in one arm then go through a machine that removes lymphocytes. The remaining blood will be returned to the participant s other arm.
Participants will stay in the hospital about 2 weeks. There they will get:
Two chemotherapy drugs by IV
Their changed cells by IV
Standard drugs for side effects
Participants will have frequent follow-up visits for 1 year, then 5 visits for the next 4 years. Then they will answer questions and have blood tests every year for 15 years.
...
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:3 - 39
Sex:All
150 Participants Needed
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Bethesda, MarylandBackground:
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.
Objective:
To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL.
Eligibility:
People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy.
Design:
Participants will be screened. This will include:
Physical exam
Blood and urine tests
Tests of their lung and heart function
Imaging scans
Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone.
Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord.
Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells.
Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment.
Participants will be admitted to the hospital. Their own modified T cells will be returned to their body.
Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:3 - 39
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Disease, Hyperleukocytosis, Pregnancy, Others
Must Not Be Taking:Antidepressants, Antineoplastics, Others
116 Participants Needed
CLIC-2201 for B-Cell Lymphoma
Toronto, OntarioThis is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies. In the proposed trial, eligible enrolled participants will undergo leukapheresis for autologous T cell collection to enable CLIC-2201 manufacturing, followed by lymphodepletion with cyclophosphamide and fludarabine, then intravenous infusion of the autologous CLIC-2201 product. The trial will use the 3+3 design to escalate or de-escalate the dose level of CLIC-2201 administered. Participants will be monitored for safety and tolerability up to day 365 following CLIC-2201 infusion.
The primary objective is to evaluate the safety and tolerability of CLIC-2201 and estimate the maximum tolerated dose (MTD) of CLIC-2201 in B-cell malignancies.
The secondary objectives are to evaluate the (i) feasibility; (ii) anti-tumour activity of CLIC-2201; (iii) and characterize the pharmacokinetic (PK) profile of CLIC-2201.
Exploratory objectives will include: i) characterizing the cellular and humoral immune responses against CLIC-2201 up to 1 year following infusion of CLIC-2201; (ii) characterizing the phenotype and gene expression profile of CLIC-2201 cells; (iii) evaluating immune and tumour cells at baseline and relapse for biomarkers of response or toxicity; (iv) evaluating serum cytokines, circulating tumour DNA (ctDNA) and B cell aplasia as biomarkers of clinical outcomes; and (v) assessing the quality of life.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:1+
Sex:All
Key Eligibility Criteria
Disqualifiers:Infections, Autoimmune Disease, GVHD, Others
Must Not Be Taking:Corticosteroids, Immunosuppressives, Chemotherapy, Others
24 Participants Needed
GFH009 for Blood Cancer
Chapel Hill, North CarolinaSLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Bulky Disease, CNS Metastases, Cardiovascular Disease, Others
Must Be Taking:Venetoclax
160 Participants Needed
CAR T-cell Therapy for Blood Cancer
Philadelphia, PennsylvaniaThis trial aims to find the safest dose of specially modified immune cells for patients with certain types of cancers that have a specific marker. These cancers include Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Acute Lymphoblastic Leukemia. The modified cells are designed to seek out and destroy cancer cells with this marker.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Infections, Cardiovascular Disability, Autoimmune Disease, Others
Must Not Be Taking:Steroids, Immunosuppressants
72 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Acute Lymphocytic Leukemia clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Acute Lymphocytic Leukemia clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Acute Lymphocytic Leukemia trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Acute Lymphocytic Leukemia is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Acute Lymphocytic Leukemia medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Acute Lymphocytic Leukemia clinical trials ?
Most recently, we added Roginolisib + Venetoclax + Rituximab for Chronic Lymphocytic Leukemia, Q702 for Blood Cancer and CLIC-2201 for B-Cell Lymphoma to the Power online platform.